Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Moderate Buy” by Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $18.5714.

LXEO has been the topic of a number of analyst reports. Chardan Capital reiterated a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a research note on Wednesday, November 5th. Guggenheim assumed coverage on Lexeo Therapeutics in a report on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Leerink Partners raised their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a report on Wednesday, October 8th.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 13,133 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $117,409.02. Following the completion of the sale, the chief executive officer owned 242,118 shares of the company’s stock, valued at approximately $2,164,534.92. This trade represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Adler sold 3,382 shares of the business’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $30,235.08. Following the transaction, the insider directly owned 73,261 shares of the company’s stock, valued at $654,953.34. The trade was a 4.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 29,091 shares of company stock valued at $232,007. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC raised its position in Lexeo Therapeutics by 10.6% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock valued at $110,000 after purchasing an additional 1,595 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Lexeo Therapeutics by 20.7% during the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after purchasing an additional 2,342 shares during the last quarter. AXQ Capital LP raised its holdings in shares of Lexeo Therapeutics by 19.6% during the 3rd quarter. AXQ Capital LP now owns 14,921 shares of the company’s stock valued at $99,000 after buying an additional 2,446 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Lexeo Therapeutics by 42.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the company’s stock worth $63,000 after buying an additional 2,799 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Lexeo Therapeutics by 22.4% in the second quarter. Bank of America Corp DE now owns 26,653 shares of the company’s stock worth $107,000 after buying an additional 4,883 shares in the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Trading Up 0.6%

Shares of LXEO stock opened at $9.04 on Friday. The firm’s 50 day moving average is $7.64 and its 200 day moving average is $5.30. The stock has a market capitalization of $659.83 million, a P/E ratio of -3.35 and a beta of 1.75. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $10.38.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.15. On average, equities analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.